Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11–12]

• Massimo Cristofanilli,
• Nadia Harbeck,
• Hope S. Rugo,
• Aurelio Castrellon,
• Anil Abraham Joy,
• Sunil Verma,
• Seock-Ah Im,
• Shrividya Iyer,
• Kathy Puyana Theall,
• Eric Gauthier,
• Xin Huang,
• Cynthia Huang Bartlett,
• Sibylle Loibl,
• Richard S. Finn

Affiliations

Massimo Cristofanilli

Northwestern University Feinberg School of Medicine, Robert H. Lurie Cancer Center, Chicago, USA; Corresponding author.

Nadia Harbeck

Brustzentrum der Universitaet Muenchen (LMU), Dept. of Obstetrics and Gynecology, München, Germany

Hope S. Rugo

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, Department of Medicine, San Francisco, USA

Aurelio Castrellon

Memorial Healthcare System, Breast Cancer Center, Hollywood, USA

Anil Abraham Joy

University of Alberta, Department of Oncology, Edmonton, Canada

Sunil Verma

University of Calgary, Tom Baker Cancer Centre, Calgary, Canada

Seock-Ah Im

Seoul National University College of Medicine, Cancer Research Institute, Seoul, South Korea

Shrividya Iyer

Pfizer Oncology, Patient and Health Impact, New York, USA

Kathy Puyana Theall

Pfizer Oncology, Global Product Development, Cambridge, USA

Eric Gauthier

Pfizer Inc, Global Product Development, San Francisco, USA

Xin Huang

Pfizer Oncology, Global Product Development, San Diego, USA

Cynthia Huang Bartlett

Pfizer Oncology, Global Medical Affairs, Collegeville, USA

Sibylle Loibl

German Breast Group, Neu-Isenburg, Germany

Richard S. Finn

David Geffen School of Medicine at University of California Los Angeles, Division of Hematology/Oncology, Santa Monica, USA